Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb Induction and Extension Study of RO7837195 in Moderately to Severely Active Ulcerative Colitis
2025-520690-39-00Phase 2Authorised
- Sponsor
- Genentech
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing RO7837195 with Placebo → RO7837195 (2 arms). Primary endpoint: Clinical remission at Week 12. Planned start Nov 2025; status: authorised.
02
Drugs
RO7837195
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-520690-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520690-39-00.